Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Daniel Childs (NPI 1851770036)

Field	Value
Entity Type	Individual
Organization	Daniel Childs
Address	200 1st St Sw
City	Rochester
State	MN
ZIP	55905
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 21, 2015

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

This provider’s commercial footprint is effectively single‑payer: lifetime Medicare revenue is $1.1M while there is no Medicaid billing on file. The absence of any Medicaid claims indicates the practice derives its reported public-payer volume and cashflows entirely from Medicare patients.

Revenue is highly concentrated in a handful of infused oncology agents: the precomputed top‑3 codes account for 84.1% of the provider’s total Medicare revenue. Those three codes are J9271 ($488.1K, 44.8%), J9144 ($273.9K, 25.1%), and J9299 ($154.6K, 14.2%), showing the practice’s financial exposure is heavily weighted to a few high-cost biologic/immunotherapy drugs.

The code mix and descriptions point to an infusion-centered medical oncology practice: the top revenue drivers are high-cost injections (J9271 – pembrolizumab, J9144 – daratumumab, J9299 – nivolumab) rather than evaluation-and-management services. E/M codes are present but small — for example, 99214 generated $11.8K (1.1%) and 99205 generated $9.1K (0.8%) — suggesting clinical workflow and revenue depend primarily on drug administration.

Operational intensity is evident in claims volume for key biologics: J9271 has 12.2K claims with an average paid of $40 and J9144 has 7.2K claims with an average paid of $38, indicating frequent administrations of these agents even though each claim’s average payment is moderate. By contrast, chemotherapy administration CPTs such as 96413 (233 claims, $24.5K, 2.2%) contribute materially less to revenue than the top biologic injectables, reinforcing a drug-revenue–dominant business model.

On competitive standing for Medicare-covered drugs, this provider is a modest, nationally typical participant rather than a dominant player. J9271 ranks #929 of 1841 (50th percentile; described as typical, unremarkable volume), J9144 ranks #351 of 615 (43th percentile; described as typical, unremarkable volume), and J9299 ranks #448 of 505 (11th percentile; described as typical, unremarkable volume) — these ranks imply the provider’s volumes are in line with many peers but not at market-leading levels.

Several secondary drug and supportive-care codes appear at low national placement but are still labeled in the source as typical in volume; for example, Q5119 contributed $21.2K (1.9%) and ranks #324 of 335 (3th percentile; described as typical, unremarkable volume), while J2506 contributed $12.6K (1.2%) and ranks #568 of 586 (1th percentile; described as typical, unremarkable volume). These line items indicate the practice uses a range of biologic and supportive agents but does not show broad national leadership for those specific products.

The practice’s revenue profile suggests limited diversification beyond infused oncology drugs: many add‑on and administration codes appear with modest revenue (e.g., 96417 $4.5K, 0.4%; 96401 $6.3K, 0.6%), implying that supply‑and‑administration services and longer infusion-hour billings are present but secondary. That pattern can inform payer strategies around site-of-care management and drug utilization reviews, since drug costs dominate the Medicare payments reported.

The provider has an established billing history, with the NPI enumerated on 2015-05-21 (~11 years ago), which supports interpretation of the observed pattern as a sustained operating model rather than a transient billing profile. Given the long tenure and concentrated drug-revenue mix, analyses of trend over time and comparisons to local infusion centers would help assess whether the provider’s code mix is stable or shifting among immunotherapy and monoclonal antibody agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	12,200	$40	$488.1K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,210	$40	$273.9K
J9299	Injection, nivolumab, 1 mg	6,440	$20	$154.6K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	2,730	$10	$27.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	230	$110	$24.5K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	920	$20	$21.2K
Q5116	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg	580	$20	$13.9K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	160	$80	$12.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	120	$100	$11.8K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	60	$160	$9.1K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Daniel Childs — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	70	7,200	$40	$323.3K
J9144	4	50	3,780	$40	$163.7K
J9299	7	20	5,240	$20	$159.4K
J2506	15	20	290	$80	$34.3K
Q5119	26	30	1,380	$20	$29.5K
J9264	5	10	2,760	$10	$27.1K
J9217	73	80	80	$130	$17.1K
Q5116	1	10	510	$20	$11.6K
96413	37	230	70	$100	$11.5K
99214	2,792	10,100	70	$80	$8.1K

Showing 1–10 of 46

Nearby Providers

Other providers in the same ZIP code as Daniel Childs, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$74.3M
Mayo Collaborative Services, Inc	MN	Clinical Medical Laboratory	$6.5M	$39.2M
Mayo Clinic	MN	Clinical Medical Laboratory	$12.2M	$15.2M
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$10.9M
Mayo Foundation For Medical Education & Research	MN	Durable Medical Equipment & Medical Supplies	$9.3K	$2.8M
Vidhu Kaushik	MN	Clinical Pathology/Laboratory Medicine Physician	$59.6K	$1.9M
Roberto Leon Ferre	MN	Medical Oncology Physician	$1.3M	$0
Peter Noseworthy	MN	Cardiovascular Disease Physician	$1.1M	$0
Robert Jacobson	MN	Pediatrics Physician	$975.6K	$0
Brittany Siontis	MN	Medical Oncology Physician	$960.6K	$0

Daniel Childs — Billing Profile & Reimbursement Data

Sign up for Daniel Childs — Billing Profile & Reimbursement Data policy alerts

Daniel Childs — Billing Profile & Reimbursement Data

Sign up for Daniel Childs — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References